GMPharma Consult ApS: Financial statements 2025
CVR: 42760137
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
GMPharma Consult ApS (CVR 42760137) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -11,057 and a net result of DKK -29,176 compared with DKK -39,429 the year before. Equity in the 2025 report amounted to DKK 59,058. The solvency ratio was 81.3%.
- Gross Profit
- DKK -11,057
- Profit/Loss
- DKK -29,176
- Equity
- DKK 59,058
- Total Assets
- DKK 72,660
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -11 t. | -29 t. | 59 t. | 0 |
| 2024 | - | -35 t. | -39 t. | 88 t. | 0 |
| 2023 | 0 | -14 t. | -13 t. | 128 t. | 0 |
Official annual report
How creditworthy is GMPharma Consult ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
GMPharma Consult ApS has published its annual report for 2024. Gross profit came to DKK -34,520, and the net result was DKK -39,429.
About GMPharma Consult ApS
GMPharma Consult ApS is a Danish company of the type Anpartsselskab based in Hillerød, founded in 2021. The company is registered under the industry Anden teknisk rådgivning. The management consists of Ina Maria Carolina Glamheden-Helle. The company is owned by Startplattan 192299 Aktiebolag. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -11,057 and a net result of DKK -29,176 compared with DKK -39,429 the year before. Equity in the 2025 report amounted to DKK 59,058.